Christopher J. Logothetis
The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)Spanish Oncology Genitourinary Group(ES)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer, Lipids, and Metabolism, Cancer Genomics and Diagnostics, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment
Most-Cited Works
- → Abiraterone and Increased Survival in Metastatic Prostate Cancer(2011)4,364 cited
- → Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy(2012)2,764 cited
- → Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3(2016)1,550 cited
- → Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study(2012)1,374 cited
- → Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study(2015)1,334 cited
- Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.(1992)